ClinicalTrials.gg
Status unknownNCT03271905Updated May 21, 2019

Influence of Mechanical Ventilation Modes on the Efficacy of Nebulized Bronchodilator

An interventional study of salbutamol sulfate and ipratropium bromide and Mesh nebulization in COPD and Asthma, sponsored by Universidade Federal do Rio Grande do Norte. Status unknown at 1 site in Brazil. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-05-21.

Sponsored by Universidade Federal do Rio Grande do Norte · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified May 2019), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive — none open to participants now, 1 under way, none of them phase 3. Albuterol · Pulmonary Disease, Chronic Obstructive.

Planned enrollment
23rd of 27
10 · median 33
Started
2017
with 1 other
No phase
6 of 27
none open now
Registered
21st of 27
by date

Among the 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive, this one is the 23rd largest by planned enrollment, is one of 2 that started in 2017, is one of 6 with no phase, and was the 21st registered.

Pulmonary Disease, Chronic Obstructive

5,528 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About albuterol

Albuterol: first FDA approval 1981 (PROVENTIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

Aerosol therapy is widely used in intensive care in critically ill patients that use mechanical ventilation (MV). However, there is a lack of standardization about aerosol performance in this group of patients. Thus, this study aims to evaluate the effect of nebulization performed in different ventilatory modes on lung function and regional pulmonary distribution of critical patients with chronic obstructive pulmonary disease. It is a clinical trial, crossover, randomized, controlled and blind. Three interventions with bronchodilators will be performed: in the Pressure Controlled Ventilation mode (PCV) with positive end expiratory pressure (PEEP) = 85% of autoPEEP, in the PCV mode with PEEP = 15 cmH2Oand in the Pressure Support Mode (PSV). Pulmonary function data will be evaluated through Electrical Impedance Tomography to evaluate the efficacy of the bronchodilator in different ventilatory modes.

Read the detailed description
  1. OBJECTIVES

2.1 Primary

  • To evaluate the influence of mechanical ventilation modes in the efficacy of nebulized bronchodilator in ventilator dependent patients with obstructive pulmonary disease.

2.2 Secondary

  • To compare regional ventilation distribution through Ventilation Surface Area (VSA) and Tidal Impedance Variation (TIV or ∆Z) by electrical impedance tomography (EIT) before, immediately after, after 1hour (h), 2h and 3h of nebulized bronchodilator in pressure controlled ventilation (PCV) with and without sedative drugs, and during pressure support ventilation (PSV).
  • To compare the peak expiratory flow (PEF), change in End-Expiratory Lung Volume (dEELV), Respiratory Compliance (Crs) and Resistance (R), before, immediately after, after 1h, 2h and 3h of nebulized bronchodilator by monitoring airway pressure and EIT in ventilator modes PCV, with and without sedative drugs and PSV .
  • To compare the ventilator modes on the VSA, ∆Z, PEF, dEELV and Crs after nebulized bronchodilator and the duration of its effects during mechanical ventilation.
  • To compare two different level of PEEP during nebulized bronchodilator on PCV mode while the patient stay with sedative drugs.

    1. METHODS

3.1 Study design This is a randomized crossover, blinded clinical trial. The randomization procedure will be a simple randomization by random number table. In order to improve reliability, not transparent sealed envelopes for blind allocation will be used.

3.2 Local and study period This is a multicenter study that involve the following hospitals: Hospital Miguel Arraes - PE and Real Hospital Português de Beneficência em Pernambuco- PE. All hospitals are located in the metropolitan region of Recife, Pernambuco, Brazil and the study will be conducted from February 2016 to December 2019.

3.3 Sample The study population consist of patients with obstructive pulmonary disease admitted to intensive care unit for MV support who meet the inclusion criteria.

3.4 Sample size Patients will be identified by a daily telephone calls to the ICUs each morning for data collection. Potential candidate patients will be screened for inclusion and exclusinon criteria, after the identification of eligible patients. After consent is obtained, the research team goes to the ICU to start collecting data. The sample size will be calculated by statistical procedures after conducting a pilot study of 10 patients.

3.5 Technical procedures and tools for data collection

Prior to starting the intervention, clinical and demographic data will be collected according to the evaluation form, ( Appendix 2). After that, patients will be receive each of 4 interventions, with a minimum of 4 hours between bronchodilator administration to allow for washout.

3.5.1. Intervention Protocol 3.5.1.1. Step 1: Nebulization during Pressure Controlled Ventilation (PCV) Mode Initially the patient will be accessed when he still sedated. Two intervention will be done with a PCV mode in two different ways and the order of the procedures will be randomized.

One nebulization will be done with a standard PCV mode and parameters will be setted as follows: sufficient Δ pressure to maintain the patient's tidal volume (vt) at 6 / kg ideal weight, respiratory rate (RR) at 12 bpm, inspiratory time (Ti) up to 1 second, maintain Ti / Ttot 0.3 - 0.4 without causing dynamic AutoPEEP, decreasing waveform flow and PEEP level of 85% from static autoPEEP.

Other nebulization will be done also in PCV mode with same parameters, but the level of PEEP will be increased to 15 cmH2O. Between this two interventions will be given 4 hours for washout.

After this, we will talk to the medical staff to interrupt sedation, will be given 3 hour for wash out to start de Step 2.

3.5.1.2. Step 2: Nebulization During Pressure Support Ventilation (PSV) With a clinical progression of the patient, a 4th evaluation will be done on the first day when the patient achieve PSV mode. In this ventilation mode the patient will control the Ti, Ttot, RR and inspiratory flow so it will be set only one Δ pressure for the patient to support a Vt of 6 ml/kg. The lowest minimum value of Δ P is 10 cmH2O and the end of inspiratory phase will be determined by a decrease at 25% of the patient peak inspiratory flow.

3.5.2 Nebulization Protocol

Nebulized bronchodilator drugs will be Salbutamol Sulfate (aerolin nebulis) and ipratropium bromide (atrovent) diluted in a saline solution (saline 0.9%) in 3 ml. The vibrating Mesh nebulizer (Aeroneb Pro-X, Galway, Ireland) will be placed in the inspiratory circuit of the MV immediately before 'Y' piece using a 22 mm T adapter. The nebulizer is operated by an electric controller connected mains power. The vibrating Mesh produces aerosol with an average particle size of 5 μm and will remain on continuously until the end of nebulization.

If a heat moisture exchanger (HME) is used during mechanical ventilation, it must be removed from between the nebulizer and airway before nebulization so that it does not filter out and reduce aerosol delivered.

3.5.3 Evaluation by Electrical Impedance Tomography. TIE is a tool of obtaining transverse plane image of any section of the human body by means of low-power electric current. The image is obtained from the electric current or potential detected on the surface of the evaluated area, where each "pixel" image is its impedance or resistivity. Thus, when used in thoracic follow-up, the EIT is able to evaluate the aeration and ventilation of the patient through the following variables: distribution of regional lung ventilation by Tidal Impedance Variation (ΔZ), Ventilation Surface Area (VSA), Percentage of Recruitable Lung (PRLV), Change in End-Expiratory Lung Volume (dEELV) and Respiratory Compliance (Crs) .

Initially, to evaluate the acute pulmonary impact of nebulizer bronchodilator on different ventilatory modes, EIT will be be performed before and immediately after the aerosol administration and repeated with each ventilation mode. Furthermore, the duration of nebulization effect will be evaluated by performing EIT after 1, 2 and 3h in each ventilation mode. There will be a > 4 hour washout between bronchodilator administrations.

An impedance tomography (ENLIGHTER, Timpel, Brazil) will be used with the patient in supine position with a bed elevation of 45◦, so a belt with 32 electrodes will be applied to the chest, in the position corresponding to the 4th - 5th intercostal space on a shaved skin. Electrodes have to be positioned for reading electrocardiograms and a flow sensor that should be attached to the endotracheal tube. After this procedures recording data starts for 3 minutes.

For image acquisition, harmless electrical currents (5-8 nA, 125 KHz) will be injectates through electrode pairs in rotating sequence, and the potential differences Will be captured in other non injetantes electrode. Variations in thoracic impedance will be evaluated through a LabView software (National Instruments, USA) and the data is recorded in separate files for patients for further analysis.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with asthma or (COPD) Invasive mechanical ventilation Hemodynamically stable

Exclusion criteria

Exclusion Criteria:

Prescribed metered dose inhaler (MDI) or intravenous bronchodilators Undrained pneumothorax Bronchopleural fistula Chest trauma Tracheoesophageal fistula Tracheal granulomas Tracheal stenosis PEEP dependence

disconnection of the MV

Endotracheal tube diameter less than 7.5

Do not make part of the protocol of daily sedation

No regular ventilatory drive when with out sedation

Do not reach a minimum tidal volume 6 ml/kg with a maximum peak pressure (PIP) of 35 cmH2O (centimeter of water) during MV.

Do not use the same MV modes that will be tested in this study

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Pressure-controled-ventilation (PCV)

    Nebulization during mechanical ventilation on a pressure controled ventilation mode.

    Drug: salbutamol sulfate and ipratropium bromide · Device: Mesh nebulization

  • Experimental
    PCV and high PEEP

    Nebulization during mechanical ventilation on a pressure controled ventilation mode and PEEP = 15 cmH2O.

    Drug: salbutamol sulfate and ipratropium bromide · Device: Mesh nebulization

  • Experimental
    Pressure suport ventilation (PSV)

    Nebulization during mechanical ventilation on a pressure suport ventilation mode.

    Drug: salbutamol sulfate and ipratropium bromide · Device: Mesh nebulization

Interventions

06

What researchers measure

Primary outcomes

  1. Change in tidal Impedance Variation

    compare regional ventilation distribution by electrical impedance tomography

    Time frame: change from baseline immediately after and at 1, 2, 3 hour of nebulized bronchodilator

Secondary outcomes

  1. Change in compliance of respiratory sistem (cmH2O)

    Compare results evaluated by lung mechanics evaluation

    Time frame: change from baseline immediately after and at 1, 2, 3 hour of nebulized bronchodilator

  2. Change in peak expiratory flow (lpm)

    Compare results evaluated by EIT

    Time frame: change from baseline immediately after and at 1, 2, 3 hour of nebulized bronchodilator

  3. Change in End-Expiratory Lung Volume

    Compare results evaluated by EIT

    Time frame: change from baseline immediately after and at 1, 2, 3 hour of nebulized bronchodilator

07

Study locations

1 site
  • Cibelle Andrade Lima
    Recife, Pernambuco 50610060, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Dec 2018, 20 months.

Of 1,097 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 20 months is close to that.

Counting every sponsor, half of 1,185 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2017
First posted
Sep 5, 2017
StartActual
Apr 10, 2017
Primary completionActual
Dec 10, 2018
CompletionEst.
Dec 10, 2019
Last update
May 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03271905
Lead sponsor
Universidade Federal do Rio Grande do Norte
Responsible party
Cibelle Andrade Lima (Principal Investigator, Universidade Federal do Rio Grande do Norte) — Principal investigator
First posted
Sep 5, 2017
Start date
Apr 10, 2017
Primary completion
Dec 10, 2018
Completion
Dec 10, 2019 (estimated)
Last update
May 21, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albuterol · Ipratropium

Start the discussion